vs

Side-by-side financial comparison of FIRST CAPITAL INC (FCAP) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

FIRST CAPITAL INC is the larger business by last-quarter revenue ($13.5M vs $12.5M, roughly 1.1× Avidity Biosciences, Inc.). FIRST CAPITAL INC runs the higher net margin — 36.2% vs -1398.3%, a 1434.5% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 19.0%). FIRST CAPITAL INC produced more free cash flow last quarter ($19.9M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 13.4%).

Capital First Ltd, formerly known as Future Capital Holdings, was an Indian non-bank financial institution which provided debt financing. In December 2018, it was merged into IDFC Bank to form IDFC First Bank. The company was listed on the NSE and BSE prior to the merger.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FCAP vs RNA — Head-to-Head

Bigger by revenue
FCAP
FCAP
1.1× larger
FCAP
$13.5M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+415.1% gap
RNA
434.0%
19.0%
FCAP
Higher net margin
FCAP
FCAP
1434.5% more per $
FCAP
36.2%
-1398.3%
RNA
More free cash flow
FCAP
FCAP
$176.8M more FCF
FCAP
$19.9M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
13.4%
FCAP

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FCAP
FCAP
RNA
RNA
Revenue
$13.5M
$12.5M
Net Profit
$4.9M
$-174.4M
Gross Margin
Operating Margin
-1513.5%
Net Margin
36.2%
-1398.3%
Revenue YoY
19.0%
434.0%
Net Profit YoY
49.6%
-117.0%
EPS (diluted)
$1.45
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FCAP
FCAP
RNA
RNA
Q4 25
$13.5M
Q3 25
$13.3M
$12.5M
Q2 25
$12.4M
$3.8M
Q1 25
$11.4M
$1.6M
Q4 24
$11.3M
$3.0M
Q3 24
$10.9M
$2.3M
Q2 24
$10.7M
$2.0M
Q1 24
$10.5M
$3.5M
Net Profit
FCAP
FCAP
RNA
RNA
Q4 25
$4.9M
Q3 25
$4.5M
$-174.4M
Q2 25
$3.8M
$-157.3M
Q1 25
$3.2M
$-115.8M
Q4 24
$3.3M
$-102.3M
Q3 24
$2.9M
$-80.4M
Q2 24
$2.8M
$-70.8M
Q1 24
$3.0M
$-68.9M
Operating Margin
FCAP
FCAP
RNA
RNA
Q4 25
Q3 25
41.8%
-1513.5%
Q2 25
37.2%
-4448.7%
Q1 25
34.2%
-8360.9%
Q4 24
34.8%
-4069.6%
Q3 24
31.5%
-4200.9%
Q2 24
31.1%
-4040.4%
Q1 24
33.0%
-2178.6%
Net Margin
FCAP
FCAP
RNA
RNA
Q4 25
36.2%
Q3 25
33.8%
-1398.3%
Q2 25
30.4%
-4089.3%
Q1 25
28.3%
-7360.0%
Q4 24
28.8%
-3439.5%
Q3 24
26.5%
-3441.7%
Q2 24
26.5%
-3461.8%
Q1 24
28.1%
-1943.4%
EPS (diluted)
FCAP
FCAP
RNA
RNA
Q4 25
$1.45
Q3 25
$1.34
$-1.27
Q2 25
$1.13
$-1.21
Q1 25
$0.97
$-0.90
Q4 24
$0.97
$-0.80
Q3 24
$0.87
$-0.65
Q2 24
$0.85
$-0.65
Q1 24
$0.88
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FCAP
FCAP
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$137.8M
$1.9B
Total Assets
$1.3B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FCAP
FCAP
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Stockholders' Equity
FCAP
FCAP
RNA
RNA
Q4 25
$137.8M
Q3 25
$132.4M
$1.9B
Q2 25
$123.2M
$1.2B
Q1 25
$120.1M
$1.3B
Q4 24
$114.6M
$1.4B
Q3 24
$116.8M
$1.5B
Q2 24
$107.8M
$1.2B
Q1 24
$105.7M
$830.9M
Total Assets
FCAP
FCAP
RNA
RNA
Q4 25
$1.3B
Q3 25
$1.2B
$2.1B
Q2 25
$1.2B
$1.4B
Q1 25
$1.2B
$1.5B
Q4 24
$1.2B
$1.6B
Q3 24
$1.2B
$1.6B
Q2 24
$1.2B
$1.3B
Q1 24
$1.2B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FCAP
FCAP
RNA
RNA
Operating Cash FlowLast quarter
$21.3M
$-156.2M
Free Cash FlowOCF − Capex
$19.9M
$-156.9M
FCF MarginFCF / Revenue
147.7%
-1257.6%
Capex IntensityCapex / Revenue
10.0%
5.7%
Cash ConversionOCF / Net Profit
4.36×
TTM Free Cash FlowTrailing 4 quarters
$35.3M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FCAP
FCAP
RNA
RNA
Q4 25
$21.3M
Q3 25
$7.9M
$-156.2M
Q2 25
$3.7M
$-199.7M
Q1 25
$4.4M
$-124.8M
Q4 24
$22.3M
$-99.9M
Q3 24
$7.6M
$-65.6M
Q2 24
$3.5M
$-65.0M
Q1 24
$7.2M
$-70.4M
Free Cash Flow
FCAP
FCAP
RNA
RNA
Q4 25
$19.9M
Q3 25
$7.8M
$-156.9M
Q2 25
$3.5M
$-203.0M
Q1 25
$4.2M
$-128.6M
Q4 24
$21.6M
$-103.8M
Q3 24
$7.5M
$-67.3M
Q2 24
$3.3M
$-65.5M
Q1 24
$7.1M
$-71.3M
FCF Margin
FCAP
FCAP
RNA
RNA
Q4 25
147.7%
Q3 25
58.6%
-1257.6%
Q2 25
27.8%
-5277.1%
Q1 25
36.5%
-8174.3%
Q4 24
190.7%
-3491.0%
Q3 24
68.6%
-2881.8%
Q2 24
31.2%
-3204.6%
Q1 24
67.2%
-2012.3%
Capex Intensity
FCAP
FCAP
RNA
RNA
Q4 25
10.0%
Q3 25
1.2%
5.7%
Q2 25
2.2%
86.9%
Q1 25
1.9%
238.6%
Q4 24
6.3%
131.7%
Q3 24
0.8%
72.9%
Q2 24
1.4%
26.0%
Q1 24
1.5%
25.8%
Cash Conversion
FCAP
FCAP
RNA
RNA
Q4 25
4.36×
Q3 25
1.77×
Q2 25
0.99×
Q1 25
1.36×
Q4 24
6.84×
Q3 24
2.62×
Q2 24
1.23×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons